Literature DB >> 20081380

Differential effects of IL-2 and IL-21 on expansion of the CD4+ CD25+ Foxp3+ T regulatory cells with redundant roles in natural killer cell mediated antibody dependent cellular cytotoxicity in chronic lymphocytic leukemia.

Aruna Gowda1, Asha Ramanunni, Carolyn Cheney, Darlene Rozewski, Wayne Kindsvogel, Amy Lehman, David Jarjoura, Michael Caligiuri, John C Byrd, Natarajan Muthusamy.   

Abstract

CD4(+) CD25(+) regulatory T cells are expanded in solid and hematological malignancies including chronic lymphocytic leukemia (CLL). Several cytokines and co-stimulatory molecules are required for generation, survival and maintenance of their suppressive effect. We and others have shown direct cytotoxic effect of the novel common gamma chain cytokine interleukin (IL)-21 on primary B cells from CLL patients. Since members of this family of cytokines are known to exhibit their effects on diverse immune cells, we have examined the effects of IL-21 on CLL patient derived regulatory T cell (Treg) induction, expansion and the inhibitory effect on natural killer cells in vitro. We demonstrate here the expression of IL-21 receptor in CD4(+)CD25(High) regulatory cells from CLL patients. In contrast to IL-2, the IL-21 cytokine failed to mediate expansion of regulatory T cells or induced expression of Foxp3 in CD4(+)CD25(Intermediate) or CD4(+)CD25(Dim/-) T cells in whole blood derived from CLL patients. Interestingly, in contrast to their differential effects on expansion of the CD4(+)CD25(+)Foxp3(+)T cells, IL-2 and IL-21 exhibited a redundant role in Treg mediated suppression of NK cell mediated antibody dependent cytotoxicity function. Given the infusion related toxicities and pro-survival effect of IL-2 in CLL, these studies provide a rationale to explore IL-21 as an alternate gamma chain cytokine in CLL therapy.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20081380      PMCID: PMC2828576          DOI: 10.4161/mabs.2.1.10561

Source DB:  PubMed          Journal:  MAbs        ISSN: 1942-0862            Impact factor:   5.857


  26 in total

1.  Cutting edge: IL-2 is critically required for the in vitro activation of CD4+CD25+ T cell suppressor function.

Authors:  Angela M Thornton; Erin E Donovan; Ciriaco A Piccirillo; Ethan M Shevach
Journal:  J Immunol       Date:  2004-06-01       Impact factor: 5.422

Review 2.  IL-2, regulatory T cells, and tolerance.

Authors:  Brad H Nelson
Journal:  J Immunol       Date:  2004-04-01       Impact factor: 5.422

3.  Efficient infection of human natural killer cells with an EBV/retroviral hybrid vector.

Authors:  Brian Becknell; Rossana Trotta; Jianhua Yu; Wei Ding; Hsiaoyin C Mao; Tiffany Hughes; Trent Marburger; Michael A Caligiuri
Journal:  J Immunol Methods       Date:  2004-12-08       Impact factor: 2.303

4.  Effect of alemtuzumab on neoplastic B cells.

Authors:  Josée Golay; Massimiliano Manganini; Alessandro Rambaldi; Martino Introna
Journal:  Haematologica       Date:  2004-12       Impact factor: 9.941

5.  Multiple immuno-regulatory defects in type-1 diabetes.

Authors:  Anjli Kukreja; Giulia Cost; John Marker; Chenhui Zhang; Zhong Sun; Karen Lin-Su; Svetlana Ten; Maureen Sanz; Mark Exley; Brian Wilson; Steven Porcelli; Noel Maclaren
Journal:  J Clin Invest       Date:  2002-01       Impact factor: 14.808

6.  Homeostatic expansion of T cells during immune insufficiency generates autoimmunity.

Authors:  Cecile King; Alex Ilic; Kersten Koelsch; Nora Sarvetnick
Journal:  Cell       Date:  2004-04-16       Impact factor: 41.582

Review 7.  CD4+ CD25+ suppressor T cells: more questions than answers.

Authors:  Ethan M Shevach
Journal:  Nat Rev Immunol       Date:  2002-06       Impact factor: 53.106

8.  Activation requirements for the induction of CD4+CD25+ T cell suppressor function.

Authors:  Angela M Thornton; Ciriaco A Piccirillo; Ethan M Shevach
Journal:  Eur J Immunol       Date:  2004-02       Impact factor: 5.532

9.  A randomized phase II trial of continuous infusion interleukin-2 or bolus injection interleukin-2 plus lymphokine-activated killer cells for advanced renal cell carcinoma.

Authors:  G R Weiss; K A Margolin; F R Aronson; M Sznol; M B Atkins; J P Dutcher; E R Gaynor; D H Boldt; J H Doroshow; M H Bar
Journal:  J Clin Oncol       Date:  1992-02       Impact factor: 44.544

10.  CD4(+)CD25(+) regulatory T cells can mediate suppressor function in the absence of transforming growth factor beta1 production and responsiveness.

Authors:  Ciriaco A Piccirillo; John J Letterio; Angela M Thornton; Rebecca S McHugh; Mizuko Mamura; Hidekazu Mizuhara; Ethan M Shevach
Journal:  J Exp Med       Date:  2002-07-15       Impact factor: 14.307

View more
  12 in total

1.  The natural product phyllanthusmin C enhances IFN-γ production by human NK cells through upregulation of TLR-mediated NF-κB signaling.

Authors:  Youcai Deng; Jianhong Chu; Yulin Ren; Zhijin Fan; Xiaotian Ji; Bethany Mundy-Bosse; Shunzong Yuan; Tiffany Hughes; Jianying Zhang; Baljash Cheema; Andrew T Camardo; Yong Xia; Lai-Chu Wu; Li-Shu Wang; Xiaoming He; A Douglas Kinghorn; Xiaohui Li; Michael A Caligiuri; Jianhua Yu
Journal:  J Immunol       Date:  2014-08-13       Impact factor: 5.422

Review 2.  Coevolution of Leukemia and Host Immune Cells in Chronic Lymphocytic Leukemia.

Authors:  Noelia Purroy; Catherine J Wu
Journal:  Cold Spring Harb Perspect Med       Date:  2017-04-03       Impact factor: 6.915

Review 3.  The clinical application of monoclonal antibodies in chronic lymphocytic leukemia.

Authors:  Samantha M Jaglowski; Lapo Alinari; Rosa Lapalombella; Natarajan Muthusamy; John C Byrd
Journal:  Blood       Date:  2010-07-07       Impact factor: 22.113

4.  A phase I dose-finding trial of recombinant interleukin-21 and rituximab in relapsed and refractory low grade B-cell lymphoproliferative disorders.

Authors:  John M Timmerman; John C Byrd; David J Andorsky; Reiko E Yamada; Janet Kramer; Natarajan Muthusamy; Naomi Hunder; John M Pagel
Journal:  Clin Cancer Res       Date:  2012-08-14       Impact factor: 12.531

5.  C-C motif chemokine 22 predicts postoperative prognosis and adjuvant chemotherapeutic benefits in patients with stage II/III gastric cancer.

Authors:  Songyang Wu; Hongyong He; Hao Liu; Yifan Cao; Rochen Li; Heng Zhang; He Li; Zhenbin Shen; Jing Qin; Jiejie Xu
Journal:  Oncoimmunology       Date:  2018-03-06       Impact factor: 8.110

Review 6.  Inflammation and survival pathways: chronic lymphocytic leukemia as a model system.

Authors:  Lisa S Chen; Kumudha Balakrishnan; Varsha Gandhi
Journal:  Biochem Pharmacol       Date:  2010-08-07       Impact factor: 5.858

Review 7.  Regulatory T cells in chronic lymphocytic leukemia: implication for immunotherapeutic interventions.

Authors:  Farhad Jadidi-Niaragh; Ghasem Ghalamfarsa; Mehdi Yousefi; Mina Hajifaraj Tabrizi; Fazel Shokri
Journal:  Tumour Biol       Date:  2013-05-17

Review 8.  Role of common-gamma chain cytokines in NK cell development and function: perspectives for immunotherapy.

Authors:  Raffaella Meazza; Bruno Azzarone; Anna Maria Orengo; Silvano Ferrini
Journal:  J Biomed Biotechnol       Date:  2011-06-13

9.  IL-21 promotes the expansion of CD27+ CD28+ tumor infiltrating lymphocytes with high cytotoxic potential and low collateral expansion of regulatory T cells.

Authors:  Saskia J A M Santegoets; Annelies W Turksma; Megan M Suhoski; Anita G M Stam; Steve M Albelda; Erik Hooijberg; Rik J Scheper; Alfons J M van den Eertwegh; Winald R Gerritsen; Daniel J Powell; Carl H June; Tanja D de Gruijl
Journal:  J Transl Med       Date:  2013-02-12       Impact factor: 5.531

Review 10.  Natural Killer Cell-Based Therapies Targeting Cancer: Possible Strategies to Gain and Sustain Anti-Tumor Activity.

Authors:  Carin I M Dahlberg; Dhifaf Sarhan; Michael Chrobok; Adil D Duru; Evren Alici
Journal:  Front Immunol       Date:  2015-11-30       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.